FDA Warning Letters · November 3, 2026 · Primary source
Conroe Welding Supply, Inc.
Summary
FDA issued a warning letter dated October 29, 2026, to Conroe Welding Supply, Inc., a medical gas manufacturer in Conroe, Texas, citing significant CGMP violations under 21 CFR Part 213. The violations include failure to perform required identity and strength testing of finished Oxygen, USP batches before release, with one incident revealing a container labeled as medical oxygen that contained up to 99% of an undisclosed contaminant instead of oxygen. FDA also cited failure to perform identity testing on incoming designated medical gas lots and failure to validate supplier certificate of analysis reliability at appropriate intervals. The letter follows a March-April 2026 inspection and requires a comprehensive independent laboratory assessment and remediation plan.
What this may mean
The warning letter puts Conroe Welding Supply at risk of regulatory or legal action, including potential seizure, injunction, or import alert, if CGMP deficiencies under 21 CFR Part 213 are not promptly corrected. The violations affect Oxygen, USP distributed to hospital and clinical settings, raising product safety and supply concerns for healthcare facilities that source medical gases from this manufacturer. FDA's new medical gas CGMP regulations, effective December 18, 2025, codified in 21 CFR Parts 213 and 230, govern the applicable quality standards.
Informational only. Not legal, medical, financial, or other professional advice. Always consult a qualified professional familiar with your specific facts before relying on any item.
Related items
- FDA Warning Letters · November 5, 2026RonanRx, Inc. dba RonanRxScore 60
- FDA Warning Letters · October 29, 2026Amgen Inc.Score 50
- FDA Warning Letters · October 27, 2026Calibrate IV HydrationScore 50
- FDA Warning Letters · November 3, 2026Guangdong Bangze Medicine Co., Ltd.Score 46
- FDA Warning Letters · October 20, 2026Signature Formulations LLCScore 46
- FDA Warning Letters · October 20, 2026Rohto Pharmaceutical Co., Ltd.Score 43